Dow Jones received a payment from EQS/DGAP to publish this press release.
DGAP-Media / 2019-03-12 / 07:00
*Probiodrug to attend BIO Europe Spring in March 2019*
*HALLE (SAALE), Germany, 12 March 2019* - Probiodrug AG ("Probiodrug",
Euronext: PBD), a clinical stage biopharmaceutical company developing novel
therapeutic solutions to treat Alzheimer's disease, announces that the
company is scheduled to attend the following conference:
*(1) *BIO Europe Spring [1]
March 25-27, 2019, Messe Wien Exhibition and Congress Center, Vienna,
Austria
*Dr. Ulrich Dauer, CEO, and Dr. Michael Schaeffer, CBO, to attend and host
meetings*
At BIO-Europe Spring, there are plenty of opportunities to network - between
partnering meetings, program sessions, during lunch, receptions, in the
exhibition, and our special evening networking receptions.
###
*For more information, please contact:*
*Probiodrug *
Dr. Ulrich Dauer, CEO
Email: contact@probiodrug.com
*MC Services AG*
Anne Hennecke, Susanne Kutter
Tel: +49 (0) 211 529 252 27
Email: probiodrug@mc-services.eu
*Notes to Editors:
About Probiodrug AG*
Headquartered in Halle (Saale), Germany, Probiodrug AG (Euronext Amsterdam:
PBD) is a clinical stage biopharmaceutical company focused on the
development of new therapeutic products for the treatment of Alzheimer's
disease (AD). Probiodrug has identified a new therapeutic concept linked to
disease initiation and progression. The development approaches are targeting
a key neuro-/synaptotoxic component of the pathology, pyroglutamate-Abeta
(pGlu-Abeta) as a therapeutic strategy. The enzyme Glutaminyl Cyclase (QC)
plays a central role in this process.
Its lead product, PQ912, has successfully completed a Phase 2a (SAPHIR)
study. The company's pipeline also includes PBD-C06, an
anti-pGlu-Abeta-specific monoclonal antibody, in preclinical development.
Probiodrug has medical use and composition of matter patents related to the
inhibition of QC and anti-pGlu-Abeta-specific monoclonal antibodies, and
has, in the Company's view, a leading position in this field of research.
*About PQ912*
PQ912, is a first-in-class, highly specific and potent inhibitor of
Glutaminyl Cyclase (QC), the enzyme catalyzing the formation of synaptotoxic
pGlu-Abeta. PQ912 has shown therapeutic effects in AD animal models. A
Phase-1 study in healthy young and elderly volunteers revealed a dose
dependent exposure and showed good safety and tolerability up to the highest
dose resulting in >90% target occupancy in the spinal fluid. In June 2017,
Probiodrug announced top-line data of the Phase 2a SAPHIR trial of PQ912 and
presented the study results at CTAD 2017. Results strongly support (a) the
hypothesis of pGlu-Abeta being synaptotoxic and (b) the therapeutic concept
pursued by Probiodrug. The study provides important guidance how to move
forward with the development of PQ912 as a disease-modifying drug for AD.
Altogether, the results make the program highly attractive for further
development; the company has initiated the preparation of a Phase 2b core
program.
www.probiodrug.com [2]
*About Alzheimer's disease*
Alzheimer's disease is a neurological disorder, which is the most common
form of dementia, and ultimately leads to death. Today, 50 million people
live with dementia worldwide, and this number is projected to treble to more
than 152 million by 2050, as the global population ages. Dementia also has a
huge economic impact. Alzheimer's has an estimated, global societal cost of
US$ 1 trillion, and it will become 2 trillion dollar disease by 2030. (World
Alzheimer Report 2018).
*Forward Looking Statements*
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgment of
Probiodrug AG as of the date of this press release. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety
of risks and uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those contemplated in
these forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in
events, conditions or circumstances on which any such statement is based.
End of Media Release
Issuer: Probiodrug AG
Key word(s): Events
2019-03-12 Dissemination of a Press Release, transmitted by DGAP - a service
of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Probiodrug AG
Weinbergweg 22
06120 Halle/Saale
Germany
Phone: +49 (0)345 555 9900
Fax: +49 (0)345 555 9901
E-mail: contact@probiodrug.de
Internet: www.probiodrug.de
ISIN: DE0007921835
WKN: 792183
Listed: Regulated Unofficial Market in Berlin, Frankfurt, Munich,
Stuttgart; Amsterdam
End of News DGAP Media
786049 2019-03-12
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=e79c5669117b1e03b0f2344537b241cb&application_id=786049&site_id=vwd&application_name=news
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=d41768cf065bad2dae80502271452537&application_id=786049&site_id=vwd&application_name=news
(END) Dow Jones Newswires
March 12, 2019 02:00 ET (06:00 GMT)
© 2019 Dow Jones News
